Thermal investigations on γ-radiation processed natural medicinal products (Ashwagandha,Amla and Hartiki)

DSC and TG studies were carried out on -radiation processed Indian natural products of medicinal importance, namely Ashwagandha (Withania Somnifera), Amla (Emblica Officinalis) and Hartiki (Terminalia chebula). DSC thermoanalytical curves were recorded from 35 to 400°C in air and nitrogen atmosphere. Similarly, TG thermoanalytical curves were taken from 35 to 700°C in air and nitrogen atmosphere. Irradiated products gave significantly different thermoanalytical profiles in comparison to non-irradiated samples. The differences were observed above decomposition temperature of 200°C and were non-linear with respect to radiation dose. Partial oxidation of the products during irradiation in air could be responsible for the observed differences.     

Unraveling the mystery of efficacy in Chinese medicine formula: New approaches and technologies for research on pharmacodynamic substances

Traditional Chinese medicine (TCM) is the key to unlock treasures of Chinese civilization. TCM and its compound play a beneficial role in medical activities to cure diseases, especially in major public health events such as novel coronavirus epidemics across the globe. The chemical composition in Chinese medicine formula is complex and diverse, but their effective substances resemble “mystery boxes”. Revealing their active ingredients and their mechanisms of action has become focal point and difficulty of research for herbalists. Although the existing research methods are numerous and constantly updated iteratively, there is remain a lack of prospective reviews. Hence, this paper provides a comprehensive account of existing new approaches and technologies based on previous studies with an in vitro to in vivo perspective. In addition, the bottlenecks of studies on Chinese medicine formula effective substances are also revealed. Especially, we look ahead to new perspectives, technologies and applications for its future development. This work reviews based on new perspectives to open horizons for the future research. Consequently, herbal compounding pharmaceutical substances study should carry on the essence of TCM while pursuing innovations in the field.     

Determination of gastrodin,p-hydroxybenzyl alcohol, vanillyl alcohol,p-hydroxylbenzaldehyde and vanillin in tall gastrodia tuber by high-performance liquid chromatography

Summary A high-performance liquid chromatographic method for the separation and determination of gastrodin,p-hydroxybenzyl alcohol, vanillyl alcohol,p-hydroxylbenzaldehyde and vanillin in extract of Chinese herbal medicine tall gastrodia tuber (Chinese name: Tianma) was established. The chromatographic conditions were optimized by means of computer-assisted method development technique. Dry-Lab software was used to model the retention behavior of the compounds as a function of gradient conditions, based on the data from two scouting gradient runs. Under the optimized conditions: column, Kromasil-C18, 5 μm, 15×0.46-cm; solvent A, water; solvent B, methanol; gradient, 5/44/65/65% B at 0/9/12/15 min; flow rate, 1.00 mL min⁻¹; temperature, ambient, the quality of tall gastrodia tubers from different sources and tianma injection were examined.     

老年人的合理用药

老年人由于组织器官的老化和功能减退，影响药物的吸收、分布、代谢和排泄。为确保老年患者的用药安全，应提高老年人的合理用药水平。     

HPLC Method for Determination of Rosiglitazone in Plasma

A fast and sensitive high performance liquid chromatography method for quantitative determination of rosiglitazone in human plasma has been developed. The extraction from plasma was performed using solid-phase extraction (SPE) on C4 silica (100 mg) disposable extraction cartridges (DEC). The separation of rosiglitazone and two metabolites was achieved on a Phenomenex® Synergi 4 µm MAX-RP (150 × 4.6 mm) column, protected by a guard column. The mobile phase was 0.01 M ammonium acetate, pH 7.0 - acetonitrile (65:35, v/v). (3S)-3-OH-quinidine was used as internal standard. The analytes were detected using fluorescence detection. The method was validated. The limit of quantitation was 1 ng mL⁻¹ and the detection limit was 0.25 ng mL⁻¹ for rosiglitazone in human plasma. The recovery was 90% for rosiglitazone. Linearity was observed over a range of 1-1000 ng mL⁻¹ (r²=0.9959). The intra- and inter-day precision (C.V.) did not exceed 8.7 %. Applicability of the method was demonstrated by a clinical pharmacokinetic study. A healthy volunteer received in two separate phases 4 mg and 8 mg rosiglitazone maleate as a single oral dose. Plasma concentrations were measured for 24 h in both phases.     

Small-volume radial flow cell for all-solid-state ion-selective electrodes

A flow cell with a radial distribution of four all-solid-state ion selective electrodes (ISEs), or alternatively three ISEs and one reference electrode, was designed and optimized for mass production. The radial distribution of the electrodes reduces the cell volume and is expected to minimize cross-contamination between different electrodes. Two different cell prototypes were developed and tested for all-solid-state K⁺-ISEs based on a solvent polymeric ion-selective membrane (ISM) and a conducting polymer, poly(3,4-ethylenedioxythiophene), as solid internal contact. In the first prototype, PEDOT was electropolymerized from an aqueous solution of the monomer and the doping ion salt, sodium polystyrenesulfonate (NaPSS). The second prototype employed an aqueous dispersion of PEDOT(PSS) that is commercially available (Baytron P, Bayer AG). Compared to electrochemical synthesis, solution casting of the polymer dispersion was found to be a more advantageous method to deposit the conducting polymer layer aiming at mass production. The resulting prototypes of the flow cell had a small volume (ca. 17-37 μl), which makes them suitable for application in clinical analysis.     

The American (USA) perspective six years after implementation of CLIA'88 (Federal) regulations

 On September 1, 1992 all testing sites in the United States were required to comply with the Clinical Laboratory Improvement Amendments of 1988 (CLIA'88). These regulations, based on both total quality management (TQM) and continuous quality improvement (CQI) principles, reshaped the environment for more than 90% of laboratories. CLIA'88 represented a revolutionary change by imposing universal, uniform regulations based on test complexity for all sites examining materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of disease. CLIA'88 specifies minimum requirements for personnel, quality control, and proficiency testing (PT). In addition, laboratories are required to follow manufacturers' directions and comply with other specified good laboratory practices. PT is mandated for most of the frequently run analyses and quality assurance requirements integrate the principles of CQI as well as TQM into the regulatory process. Biannual inspection is integral to CLIA'88, however, laboratories can choose other federally approved ("deemed") professional organizations, such as the Commission on Office Laboratory Accreditation, the College of American Pathologists, or the Joint Commission on Accreditation of Healthcare Organization, having standards that meet or exceed those of CLIA'88. CLIA'88 has still not been finalized. This article discusses the impact and changes since CLIA's implementation in 1992. Received: 5 October 1998 · Accepted: 20 October 1998     

碘酸钾存在下极谱催化波法测定陈皮甙

基于陈皮甙在ＫＩＯ３存在下产生的极谱催化波，拟定了测定陈皮甙的新方法。在 ０．５５ ｍｏｌ／Ｌ ＨＡｃ－０．０１ｍｏｌ／Ｌ　ＮａＡｃ（ｐＨ ４．００±０．０５）－１．０×１０～（－３）ｍｏｌ／Ｌ ＫＩＯ３缓冲溶液中，陈皮甙催化波的峰电位为－１．３５ Ｖ（ｖｓ，ＳＣＥ），它的一阶导数峰峰电流与陈皮甙浓度在２．６ × １０～（－７）～２．６ × １０～（－６）ｍｏｌ／Ｌ范围内呈线性关系（ｒ＝０．９９７０，ｎ＝６）。本方法比现有的电化学方法灵敏度高一个数量级。可用于直接测定中草药贯众水提液中陈皮甙含量。     

2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant

Extensive structure-activity relationships (SARs) study of JND3229 was conducted to yield a series of new reversible 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidine privileged scaffold as EGFR^C797S inhibitors. One of the most potent compound 6i potently suppressed EGFR^{L858R/T790M/C797S} kinase with an IC₅₀ value of 3.1 nmol/L, and inhibited the proliferation of BaF3 cells harboring EGFR^{L858R/T790M/C797S} and EGFR^{19D/T790M/C797S} mutants with IC₅₀ values of 290 nmol/L and 316 nmol/L, respectively. Further, 6i dose-dependently induced suppression of the phosphorylation of EGFR^{L858R/T790M/C797S} and EGFR^{19D/T790M/C797S} in BaF3 cells. Compound 6i may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.